Ling Zhang

Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

David A. Sallman, Amy E. DeZern, David P. Steensma et al. · Blood · 2018 · 67 citations

Sociodemographic and clinical features of bipolar disorder patients misdiagnosed with major depressive disorder in <scp>C</scp>hina

Yu‐Tao Xiang, Ling Zhang, Gang Wang et al. · Bipolar Disorders · 2013 · 49 citations

Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)

Seongseok Yun, Rohit Sharma, Onyee Chan et al. · Leukemia Research · 2019 · 24 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +10

MYC overexpression is associated with an early disease progression from MDS to AML

David Gajzer, Constantine Logothetis, David A. Sallman et al. · Leukemia Research · 2021 · 18 citations · Full text

Immunology, Pathology, Medicine +4

Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with <i>TP53</i> mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

David A. Sallman, Amy E. DeZern, Kendra Sweet et al. · Cancer Research · 2018 · 14 citations

Mixed-phenotype Acute Leukemia, Pathology, Pharmacotherapy +18